In melanoma adjuvant IFN-α studies, relapse free survival (RFS) has been the most consistent and reproducible efficacy endpoint across multiple trials.[23,24] Therefore, we used RFS as our primary efficacy endpoint for this analysis. This evidence concerns the gene IFNA2 and melanoma.